: We applied three major comorbidity scoring systems-CIRS, HCT-CI, and Severe4-to a cohort of 379 patients with LBCL treated with CAR-T therapy. A high comorbidity burden was identified in 7% to 34% of patients, depending on the score used. However, a high comorbidity burden did not negatively impact the tolerability of CAR-T treatment, including the incidence of CRS, or hematologic toxicity. The use of tocilizumab and corticosteroids was comparable between patients with low and high comorbidity burden, as was the cumulative incidence of non-relapse mortality.
Galli, E., Di Blasi, R., Pansini, I., Cristinelli, C., Bommier, C., De Bernardis, I., Corrente, A., Viscovo, M., Montini, L., Chiusolo, P., Hohaus, S., Sorà, F., Thieblemont, C., Sica, S., Frail is not fail: Limited impact of comorbidities on non‐relapse mortality and safety in patients with LBCL treated with CAR‐T, <<BRITISH JOURNAL OF HAEMATOLOGY>>, 2025; 207 (2): 642-647. [doi:10.1111/bjh.20222] [https://hdl.handle.net/10807/325421]
Frail is not fail: Limited impact of comorbidities on non‐relapse mortality and safety in patients with LBCL treated with CAR‐T
Galli, Eugenio;Di Blasi, Roberta;Pansini, Ilaria;Corrente, Alessandro;Viscovo, Marcello;Montini, Luca;Chiusolo, Patrizia;Hohaus, Stefan;Sorà, Federica;
2025
Abstract
: We applied three major comorbidity scoring systems-CIRS, HCT-CI, and Severe4-to a cohort of 379 patients with LBCL treated with CAR-T therapy. A high comorbidity burden was identified in 7% to 34% of patients, depending on the score used. However, a high comorbidity burden did not negatively impact the tolerability of CAR-T treatment, including the incidence of CRS, or hematologic toxicity. The use of tocilizumab and corticosteroids was comparable between patients with low and high comorbidity burden, as was the cumulative incidence of non-relapse mortality.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
